Biofrontera Q2 rev $9.0M (+15%); net loss $5.3M; restructures AG deal, new royalty 12-15%

Biofrontera Inc.

2025-Q2 EPS reported -$1.05 revenue$17,617,000

Q2 2025 revenue $9.0M (up 15% YoY); net loss $5.3M vs $0.3M in Q2 2024.
Adjusted EBITDA negative $5.1M vs negative $4.7M; cash $7.2M at June 30.
Acquired US IP and NDA from Biofrontera AG; new Ameluz royalty 12%/15% vs prior 25-35%.
Received $11M additional funding; US patent for revised Ameluz granted through 2043.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.